Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simvastatin combination
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Simvastatin combinations are pharmaceutical products that contain simvastatin together with one or more other active ingredients—most commonly ezetimibe or nicotinic acid. These combinations are used to treat high cholesterol and triglyceride levels in the blood and may help prevent certain types of heart problems in patients at high risk. Simvastatin is an HMG-CoA reductase inhibitor (statin) that works by blocking an enzyme needed for cholesterol synthesis in the liver. Ezetimibe is a cholesterol absorption inhibitor that reduces intestinal absorption of dietary and biliary cholesterol. Nicotinic acid (niacin) lowers LDL cholesterol and triglycerides while raising HDL cholesterol through multiple mechanisms. These fixed-dose combinations are indicated for primary hypercholesterolemia (including heterozygous familial hypercholesterolemia), homozygous familial hypercholesterolemia, mixed dyslipidemia, and prevention of cardiovascular events in appropriate populations[1][6].
- Brand names
- VytorinSimvotin TabSimcard -EZSimstat NSimlo -EZStarstat -EZ (20)Starstat -EZSimvas -EZLipicon -SSimvastol -N
- Other names
- simvastatin combination
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on simvastatin combination.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simvastatin combination.